Gordon A. Brown, DO

Patient Profile: A 60-Year-Old-Man with Prostate Cancer

A 60-year-old man presented with urinary retention, fatigue, and decreased appetite

DRE suggested mild abnormality/firmness with potential prostate cancer

Transrectal ultrasound (TRUS)-guided biopsy of the prostate confirmed Grade Group 2/stage c2b adenocarcinoma of the prostate, with 10 of 12 positive cores

Patient underwent radical prostatectomy with pelvic lymph node dissection; specimen analysis revealed margin-negative, stage pT3b, node-negative, Grade Group 2/stage IIB adenocarcinoma of the prostate

Patient achieved nadir PSA within 3 months of surgery, but PSA subsequently rose to 0.5 ng/mL

Patient then underwent salvage EBRT (2.7 Gy x 26 fractions)

6- and 7-month Post-Treatment Followup Notes (October-November 2019)

Patient’s PSA levels increased to 27.3 ng/mL in 10/2019 and 61.7 ng/mL in 11/2019.

MRI revealed two visceral metastases, one in the left lobe of the liver and one in the left superior lobe of the lung.

Given the recent findings, the patient and clinician discussed next steps for treatment. The patient noted that he still has a full-time job and enjoys being active with his family. He expressed concern about potential side effects of systemic therapy interfering with these aspects of his life.

They ultimately decided to initiate combination therapy with leuprolide and apalutamide.

Videos

Dr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.

Unmet Needs and Future Directions for Patients with Metastatic CSPC

A comparison of the safety and efficacy of available AR inhibitors and a discussion of factors that impact treatment selection in mCSPC.

A Comparison of AR Inhibitor Safety and Efficacy and Factors That Impact mCSPC Treatment Selection

Gordon A. Brown, DO, comments on adverse events observed after combination ADT/apalutamide treatment and how they might be managed.

Safety of Combination ADT/Apalutamide and Management of Adverse Events

A comprehensive review of efficacy data on combination therapy with ADT and the AR inhibitor apalutamide in patients with mCSPC.

Gordon A. Brown, DO

Articles

Unmet Needs and Future Directions for Patients with Metastatic CSPC

A Comparison of AR Inhibitor Safety and Efficacy and Factors That Impact mCSPC Treatment Selection

Safety of Combination ADT/Apalutamide and Management of Adverse Events

Efficacy Data on Combination ADT/Apalutamide from the TITAN Trial and Real-World Analyses